代谢组学在特发性肺间质纤维化中的研究进展  

Research Progress of Metabolomics in Idiopathic Pulmonary Interstitial Fibrosis

作　　者：侯西苓 赵思雯 石雪峰[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海省人民医院呼吸与危重症医学科,青海 西宁

出　　处：《临床个性化医学》2024年第1期68-73,共6页Journal of Clinical Personalized Medicine

摘　　要：特发性肺纤维化(IPF)是一种慢性间质性肺疾病,进展迅速,预后较差。该疾病诊疗困难,目前缺乏特异性生物标志物。FDA批准的唯一疗法为吡非尼酮和尼达尼布,该药物可以改善肺功能丧失,延缓疾病进展,但它们并不能改善肺功能或提供完全治愈。随着老龄化的加剧,患病率、死亡率逐渐上升,因此早诊断、早治疗,对于缓解疾病进展改善预后至关重要。代谢组学技术的出现,有助于进一步明确疾病的发病机制,为寻找有意义的生物标志物及治疗靶点奠定基础。Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease that progresses rapidly and has a poor prognosis. Diagnosis and treatment of the disease are difficult, and specific biomarkers are currently lacking. The only FDA-approved treatments are pirfenidone and Nidanib, which im-prove loss of lung function and slow disease progression, but they do not improve lung function or provide a complete cure. With the intensification of aging, morbidity and mortality are gradually increasing, so early diagnosis and treatment are crucial to alleviate disease progression and im-prove prognosis. The emergence of metabolomics technology is helpful to further clarify the patho-genesis of diseases and lay a foundation for searching for meaningful biomarkers and therapeutic targets.

关 键 词：特发性肺纤维化 代谢组学 综述 

分 类 号：R56[医药卫生—呼吸系统]